Page 6,430«..1020..6,4296,4306,4316,432..6,4406,450..»

Sigma Intros Stem Cell Medium

Posted: Published on October 6th, 2012

Sigma Life Science, the innovative biological products and services research wing of Sigma-Aldrich Corporation (SIAL), has announced the launch of Stemline pluripotent culture medium, a human pluripotent stem cell culture medium which provides a suitable environment for the long-term maintenance and growth of healthy pluripotent stem cells. Sigma-Aldrich stated that the Stemline pluripotent stem cell culture medium is serum-free, consists of fully-defined components and has 80% less basic fibroblast growth factor compared to the leading pluripotent stem cell culture medium. This provides a favorable environment for long-term maintenance of optimal growth rates, viability and pluripotency. The stem cell research community usually complains of the high costs of media for pluripotent stem cells. However, Sigma-Aldrichs Stemline pluripotent culture medium performs as good as the leading medium for maintaining pluripotency and optimal growth rates and is available at comparatively lower costs than the conventional media. It is also found that cultured pluripotent stem cells show all the established pluripotency markers and maintain proper karyotype and the ability to distinguish into each of the three germ layers. The novel Stemline media strengthens Sigma-Aldrich's position as one of the largest global providers of cell culture media. Sigma-Aldrich released its second-quarter 2012 results in July. … Continue reading

Posted in Stem Cell Research | Comments Off on Sigma Intros Stem Cell Medium

From Stem Cells To Mouse Eggs To Baby Mice – No Father Involved

Posted: Published on October 6th, 2012

Editor's Choice Academic Journal Main Category: Fertility Also Included In: Stem Cell Research Article Date: 05 Oct 2012 - 14:00 PDT Current ratings for: From Stem Cells To Mouse Eggs To Baby Mice - No Father Involved 4.4 (5 votes) 5 (1 votes) The scientists, from Kyoto University, first produced healthy mouse pups in 2011 using stem cell-derived sperm. They have now achieved the same by using eggs which were created in the same way. Scientists are describing the Kyoto team's feat as a "significant achievement" which will have a profound impact on reproductive cell biology and genetics research. In both cases, the scientists used ES (embryonic stem) cells and iPS (induced pluripotent stem) cells. ES are taken from embryos while iPS come from reprogrammed adult tissue cells that mimic stem cell behavior. Theory suggests that both ES and iPS cells can produce all the cell types in the body. However, the majority of scientists have not been able to make them turn into germ cells, which eventually become eggs or sperm. Mitinori Saitou and team hit upon a process that managed to turn stem cells into germ cells. They started off with ES and iPS cells and cultured them … Continue reading

Posted in Stem Cell Research | Comments Off on From Stem Cells To Mouse Eggs To Baby Mice – No Father Involved

BUSM study investigates genetic variants' role in increasing Parkinson's disease risk

Posted: Published on October 6th, 2012

Public release date: 5-Oct-2012 [ | E-mail | Share ] Contact: Jenny Eriksen Leary jenny.eriksen@bmc.org 617-638-6841 Boston University Medical Center (Boston) Boston University School of Medicine (BUSM) investigators have led the first genome-wide evaluation of genetic variants associated with Parkinson's disease (PD). The study, which is published online in PLOS ONE, points to the involvement of specific genes and alterations in their expression as influencing the risk for developing PD. Jeanne Latourelle, DSc, assistant professor of neurology at BUSM, served as the study's lead author and Richard H. Myers, PhD, professor of neurology at BUSM, served as the study's principal investigator and senior author. A recent paper by the PD Genome Wide Association Study Consortium (PDGC) confirmed that an increased risk for PD was seen in individuals with genetic variants in or near the genes SNCA, MAPT, GAK/DGKQ, HLA and RIT2, but the mechanism behind the increased risk was not determined. "One possible effect of the variants would be to change the manner in which a gene is expressed in the brains, leading to increased risk of PD," said Latourelle. To investigate the theory, the researchers examined the relationship between PD-associated genetic variants and levels of gene expression in brain … Continue reading

Comments Off on BUSM study investigates genetic variants' role in increasing Parkinson's disease risk

Multiple miRNA Markers Associated with Angiogenesis and Tissue Injury Repair Expressed in Cytori’s Cell Therapy

Posted: Published on October 6th, 2012

SAN DIEGO--(BUSINESS WIRE)-- Cytori Therapeutics (CYTX) announced that three oral presentations related to its cell therapy are being presented today at the 10th annual International Federation for Adipose Therapeutics and Sciences meeting. The findings provide insights into the mechanisms-of-action for Cytoris cell therapy. One study identified high levels of micro-RNA (miRNA) markers in human tissue thought to play a role in the repair of tissue injury resulting from ischemia, or lack of blood flow. Two additional characterization and comparative analysis studies on human tissue reaffirmed cellular characteristics of Cytoris cell therapy and distinguished the safety, viability and cell make-up as compared to cell outputs derived from alternate approaches. Results from all three studies have important implications for how the cells repair injured tissue and on the safety and viability of cell-based treatments derived from adipose tissue, said John Fraser, Ph.D., Chief Scientist of Cytori Therapeutics. Mechanisms identified in our miRNA analysis are consistent with our prior clinical and preclinical data, which suggest these mechanisms include angiogenesis, immune-modulation, and remodeling and wound repair. The miRNA study provides baseline data, which we can apply to our U.S. ATHENA clinical trial in refractory heart failure patients and other activities including our recently announced … Continue reading

Comments Off on Multiple miRNA Markers Associated with Angiogenesis and Tissue Injury Repair Expressed in Cytori’s Cell Therapy

Fertility hope in stem cell eggs

Posted: Published on October 5th, 2012

Hopes of a cure for infertility in humans were raised Friday after Japanese stem cell researchers announced they had created viable eggs using normal cells from adult mice. The breakthrough raises the possibility that women who are unable to produce eggs naturally could have them created in a test tube from their own cells and then planted back into their body. A team at Kyoto University harvested stem cells from mice and altered a number of genes to create cells very similar to the primordial germ cells that generate sperm in men and oocytes -- or eggs -- in women. They then nurtured these with cells that would become ovaries and transplanted the mixture into living mice, where the cells matured into fully-grown oocytes. They extracted the matured oocytes, fertilised them in vitro -- in a test tube -- and implanted them into surrogate mother mice. The resulting mice pups were born healthy and were even able to reproduce once they matured. Writing in the US journal Science, which published the findings, research leader professor Michinori Saito said the work provided a promising basis for hope in reproductive medicine. "Our system serves as a robust foundation to investigate and further … Continue reading

Posted in Mesenchymal Stem Cells | Comments Off on Fertility hope in stem cell eggs

Japan team offers fertility hope with stem cell eggs

Posted: Published on October 5th, 2012

Hopes of a cure for infertility in humans were raised Friday after Japanese stem cell researchers announced they had created viable eggs using normal cells from adult mice. The breakthrough raises the possibility that women who are unable to produce eggs naturally could have them created in a test tube from their own cells and then planted back into their body. A team at Kyoto University harvested stem cells from mice and altered a number of genes to create cells very similar to the primordial germ cells that generate sperm in men and oocytes -- or eggs -- in women. They then nurtured these with cells that would become ovaries and transplanted the mixture into living mice, where the cells matured into fully-grown oocytes. They extracted the matured oocytes, fertilised them in vitro -- in a test tube -- and implanted them into surrogate mother mice. The resulting mice pups were born healthy and were even able to reproduce once they matured. Writing in the US journal Science, which published the findings, research leader professor Michinori Saito said the work provided a promising basis for hope in reproductive medicine. "Our system serves as a robust foundation to investigate and further … Continue reading

Comments Off on Japan team offers fertility hope with stem cell eggs

OncoMed Pharmaceuticals Advances Two Notch Pathway Product Candidates in Clinical Development

Posted: Published on October 5th, 2012

REDWOOD CITY, Calif.--(BUSINESS WIRE)-- OncoMed Pharmaceuticals, Inc., a clinical stage, research and discovery company developing novel therapeutics that target cancer stem cells, today announced clinical progress with two of its Notch pathway product candidates, resulting in $8 million in milestone payments from the companys strategic collaborator GlaxoSmithKline (GSK). Anti-Notch2/3 (OMP-59R5) OncoMed has initiated a Phase 1b/2 clinical trial in its anti-Notch2/3 antibody (OMP-59R5) program. In the Phase 1b/2 ALPINE trial (Antibody therapy in first-Line Pancreatic cancer Investigating anti-Notch Efficacy and safety), Anti-Notch2/3 is being tested in combination with gemcitabine in first-line advanced pancreatic cancer patients. Following a Phase 1b safety run-in, a randomized Phase 2 clinical trial will proceed in these patients to compare the efficacy of standard-of-care gemcitabine either with Anti-Notch2/3 or with placebo. The two primary endpoints of the Phase 2 part of the trial will be progression-free survival (PFS) in the Anti-Notch2/3 arm compared to a placebo arm in all patients, as well as in patients who have a particular biomarker. Key secondary and exploratory endpoints include overall survival, response rate, and safety, and these endpoints will be assessed in all patients, as well as in the biomarker positive subset of patients. Dr. Lon Smith, from the … Continue reading

Posted in FDA Stem Cell Trials | Comments Off on OncoMed Pharmaceuticals Advances Two Notch Pathway Product Candidates in Clinical Development

StemCells, Inc. Announces First Transplant of Neural Stem Cells Into Patient in Clinical Trial for Dry Age-Related …

Posted: Published on October 5th, 2012

NEWARK, Calif., Oct. 4, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (STEM) today announced that the first patient in its Phase I/II clinical trial in dry age-related macular degeneration (AMD) has been enrolled and transplanted. The trial is designed to evaluate the safety and preliminary efficacy of the Company's proprietary HuCNS-SC(R) product candidate (purified human neural stem cells) as a treatment for dry AMD, and the patient was transplanted with the cells yesterday at the Retina Foundation of the Southwest (RFSW) in Dallas, Texas, one of the leading independent vision research centers in the United States. AMD afflicts approximately 30 million people worldwide and is the leading cause of vision loss and blindness in people over 55 years of age. "This trial signifies an exciting extension of our on-going clinical research with neural stem cells from disorders of the brain and spinal cord to now include the eye," said Stephen Huhn, MD, FACS, FAAP, Vice President and Head of the CNS Program at StemCells, Inc. "Studies in the relevant animal model demonstrate that the Company's neural stem cells preserve vision in animals that would otherwise go blind and support the therapeutic potential of the cells to halt retinal degeneration. Unlike others … Continue reading

Posted in Stem Cell Human Trials | Comments Off on StemCells, Inc. Announces First Transplant of Neural Stem Cells Into Patient in Clinical Trial for Dry Age-Related …

Stem Cell Transplant May Spur Heart Disease Risk: Study

Posted: Published on October 5th, 2012

WEDNESDAY, Oct. 3 (HealthDay News) -- People who undergo the transplantation of stem cells taken from bone marrow, circulating blood or umbilical cord blood are more likely to develop risk factors for heart disease, such as high blood pressure, diabetes and high cholesterol, a new study contends. Researchers from the American Society of Hematology noted that patients who were treated with chemotherapy or radiation before such a transplant -- called a "hematopoietic cell transplant," or HCT -- had a significantly higher risk for heart disease later in life. "While we know that heart disease is a real concern for long-term HCT survivors, small sample sizes and a lack of long-term follow-up in previous studies have only allowed us to look at a small piece of the puzzle of how this chronic condition develops in these patients," the study's first author, Dr. Saro Armenian, medical director of the Pediatric Survivorship Clinic in the Childhood Cancer Survivorship Program at City of Hope in Duarte, Calif., said in a society news release. "Our study sought to better determine the specific factors before and after transplant that can lead to heart disease in a large group of transplant recipients," Armenian explained. In conducting the … Continue reading

Comments Off on Stem Cell Transplant May Spur Heart Disease Risk: Study

FDA cracks down on websites selling bad drugs

Posted: Published on October 5th, 2012

(Reuters) - The U.S. Food and Drug Administration said it has cracked down on thousands of online pharmacies for selling potentially unsafe, unapproved or fake medicines, including the erectile dysfunction drug Viagra and antiviral Tamiflu. The FDA, working with international regulatory and law enforcement agencies from about 100 countries, said on Thursday that it took action against more than 4,100 Internet pharmacies, bringing civil and criminal charges, removing offending websites and seizing drugs worldwide. The move was part of the fifth annual International Internet Week of Action, a global effort to fight the online sale and distribution of potentially counterfeit and illegal medicine. Action taken between September 25 and October 2 resulted in the shutdown of more than 18,000 illegal pharmacy websites and the seizure of 3.7 million doses of counterfeit medicines worth an estimated $10.5 million, the agency said. Homeland Security Investigations, which took part in the coordinated effort titled Pangea, said preliminary results show the actions also accounted for 79 arrests. "Consumers in the United States and around the world face a real threat from Internet pharmacies that illegally sell potentially substandard, counterfeit, adulterated or otherwise unsafe medicines," FDA Commissioner Margaret Hamburg said in a statement. "This week's … Continue reading

Posted in Erectile Dysfunction | Comments Off on FDA cracks down on websites selling bad drugs

Page 6,430«..1020..6,4296,4306,4316,432..6,4406,450..»